Studies comparing OS and PFS with VEGF TKI-mTORi versus VEGF TKI-VEGF TKI (HR<1 favors second-line mTORi versus VEGF TKI).

CI, confidence interval; HR, hazard ratio; mTORi, mammalian target of rapamycin inhibitor; N/A, not available; OS, overall survival; PFS, progression-free survival; VEGF TKI, vascular endothelial growth factor tyrosine kinase inhibitor.aOS HRs and 95% CIs were imputed for Harrison et al. 2012, Gore et al. 2013, and Ruiz et al. 2013.bPFS HRs and 95% CIs were imputed for Heng et al. 2012 and Busch et al. 2013.cHeng et al. 2012 used prospective data collection. However, the comparative analysis was performed retrospectively.dThe PFS results for Busch et al. 2011, Heng et al. 2012, Park et al. 2012, and Busch et al. 2013 were unadjusted. Y in column adjustment refers to the OS results.eOnly one patient received axitinib in Elaidi et al. 2013. The number of patients who received axitinib was not reported in Ruiz et al. 2013. The number receiving axitinib was n = 10 in Signorovitch et al. 2013 (personal communication).Studies comparing OS and PFS with VEGF TKI-mTORi versus VEGF TKI-VEGF TKI (HR